Chorionic gonadotropin - Biologic Drug Details

Summary for chorionic gonadotropin

Tradenames:	4
High Confidence Patents:	0
Applicants:	4
BLAs:	5
Suppliers: see list	5
Recent Clinical Trials:	See clinical trials for chorionic gonadotropin
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for chorionic gonadotropin

Recent Clinical Trials for chorionic gonadotropin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Assistance Publique - Hôpitaux de Paris	Phase 3
Northwest Women's and Children's Hospital, Xi'an, Shaanxi	N/A
University of Sao Paulo General Hospital	Phase 4

See all chorionic gonadotropin clinical trials

Recent Litigation for chorionic gonadotropin

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD.	2023-01-19
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN INC.	2021-07-28
Ravgen, Inc. v. Biora Therapeutics, Inc.	2020-12-21

See all chorionic gonadotropin litigation

PTAB Litigation

Petitioner	Date
Quest Diagnostics Incorporated	2020-09-11
	2017-01-10
	2013-07-29

See all chorionic gonadotropin litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for chorionic gonadotropin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for chorionic gonadotropin Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for chorionic gonadotropin Derived from Patent Text Search

No patents found based on company disclosures

Chorionic gonadotropin Market Analysis and Financial Projection Experimental

Human Chorionic Gonadotropin (hCG) Market Dynamics and Financial Trajectory

Introduction to Human Chorionic Gonadotropin (hCG)

Human chorionic gonadotropin (hCG) is a hormone naturally produced during pregnancy, playing a crucial role in fertility treatments. It is chemically similar to luteinizing hormone and is used to signal the ovaries to release a mature egg, a process known as ovulation[2].

Market Size and Growth Projections

The global human chorionic gonadotropin market is experiencing significant growth. As of 2023, the market was estimated at approximately $758.56 million and is projected to grow to $1,522.76 million by 2034, with a compound annual growth rate (CAGR) of 6.54% from 2024 to 2034[4].

Regional Market Analysis

North America

North America holds the largest share of the hCG market, driven by the well-established healthcare infrastructure, favorable reimbursement policies, and the growing burden of infertility in the region. According to the CDC, about 1 in 5 women aged 15-49 years in the United States experience infertility, and 1 in 4 have difficulty getting pregnant or carrying a pregnancy to term[1][4].

Asia-Pacific

The Asia-Pacific region is expected to be the fastest-growing market for hCG, driven by increasing research and development, rising prevalence of infertility, advanced healthcare infrastructure, and a growing geriatric population. Countries like India, China, Singapore, and South Korea are significant contributors to this growth due to their robust pharmaceutical sectors and drug exports[1][4].

Factors Driving Market Growth

Increasing Prevalence of Infertility

The rising prevalence of infertility globally is a major driver of the hCG market. Approximately 15% of reproductive-aged couples worldwide are affected by infertility, with specific regions like the United States and India showing significant numbers of infertile individuals[1][4].

Growing Demand for Assisted Reproductive Technology (ART)

The increasing demand for ART treatments such as in vitro fertilization (IVF) and intrauterine insemination (IUI) is boosting the market. hCG injections are crucial in these treatments to precisely time ovulation and egg maturation[2][4].

Impact of COVID-19

The COVID-19 pandemic had a temporary negative impact on the hCG market due to reduced foot traffic in hospitals and clinics, and the fear of SARS-CoV-2 infection. However, with the easing of restrictions and increasing vaccinations, the market is expected to regain its growth trajectory[1].

Advances in Technology

The use of recombinant DNA technology to produce recombinant hCG is a significant factor driving market growth. This technology allows for the large-scale production of hCG, which is more efficient and reliable than native hCG production[4].

Market Concentration and Key Players

The hCG market is moderately concentrated with both international and local companies operating globally. Key players include Sanzyme, Merck & Co. Inc., Ferring BV, Fresenius Kabi AG, and Sun Pharmaceutical Industries Ltd. These companies are involved in various market strategies such as acquisitions, product development, and expansion of services to maintain their market share[1].

Therapeutic Applications of hCG

Fertility Treatments

hCG injections play a critical role in fertility treatments like IUI and IVF by triggering ovulation and the final maturation of eggs. They also support the early stages of pregnancy by helping the body produce progesterone, a hormone essential for maintaining a healthy pregnancy[2].

Other Uses

Apart from fertility treatments, hCG is used in various other medical applications, including the treatment of hypogonadism and as a diagnostic tool for pregnancy duration[2][5].

Financial Trajectory

The financial trajectory of the hCG market is promising, with a projected CAGR of 6.54% from 2024 to 2034. The market is expected to more than double in size over this period, driven by the factors mentioned above. Investments in research and development, expansion of healthcare infrastructure, and favorable reimbursement policies are expected to continue driving growth[4].

Market News and Developments

Recent developments in the hCG market include the launch of new services and products. For example, Inception Fertility expanded its ecosystem to include HavenCryo, a long-term reproductive tissue and cryopreservation storage solution. Additionally, Merck acquired Acceleron for $11.5 billion, further consolidating the market[1].

Challenges and Opportunities

Challenges

Despite the growth, the hCG market faces challenges such as the temporary impact of the COVID-19 pandemic and the need for continuous innovation to meet the increasing demand for ART treatments.

Opportunities

The growing awareness about infertility, increasing investments in the pharmaceutical sector, and advancements in recombinant DNA technology present significant opportunities for market growth. The expansion of healthcare infrastructure in emerging markets also offers potential for further market penetration[1][4].

Key Takeaways

• The global hCG market is projected to grow significantly, driven by the increasing prevalence of infertility and the growing demand for ART treatments.
• North America currently holds the largest market share, while the Asia-Pacific region is expected to be the fastest-growing market.
• Recombinant hCG production is a key driver of market growth due to its efficiency and reliability.
• Major players are investing heavily in research and development and expanding their services to maintain market share.
• The market faces temporary challenges but has substantial long-term growth potential.

FAQs

What is the current size of the Human Chorionic Gonadotropin Market?

The global human chorionic gonadotropin market was estimated at approximately $758.56 million in 2023[4].

Who are the key players in the Human Chorionic Gonadotropin Market?

Key players include Sanzyme, Merck & Co. Inc., Ferring BV, Fresenius Kabi AG, and Sun Pharmaceutical Industries Ltd[1].

Which region is expected to grow the fastest in the Human Chorionic Gonadotropin Market?

The Asia-Pacific region is projected to be the fastest-growing market for hCG[1][4].

What are the primary uses of Human Chorionic Gonadotropin in fertility treatments?

hCG is used to trigger ovulation and the final maturation of eggs in treatments like IUI and IVF, and to support the early stages of pregnancy by helping the body produce progesterone[2].

How has the COVID-19 pandemic impacted the Human Chorionic Gonadotropin Market?

The COVID-19 pandemic temporarily reduced the growth of the hCG market due to decreased foot traffic in hospitals and clinics and the fear of SARS-CoV-2 infection, but the market is expected to regain its growth trajectory with the easing of restrictions[1].

Sources

1. Mordor Intelligence: Human Chorionic Gonadotropin Market Size & Share Analysis.
2. VFP Pharmacy Group: hCG Injections: Understanding Their Role in Fertility Treatment.
3. Market Research Intellect: Rapport sur la taille, la portée et les prévisions du marché de la gonadotrophine chorionique pour injection.
4. Towards Healthcare: Human Chorionic Gonadotropin Market | North America Leads.
5. Wiley Online Library: Human chorionic gonadotropin as a measure of pregnancy duration.